Le Prell, Colleen G.2020-03-192020-03-1920190734-0451http://dx.doi.org/10.1055/s-0039-1684045https://hdl.handle.net/10735.1/7412Due to copyright restrictions and/or publisher's policy full text access from Treasures at UT Dallas is limited to current UTD affiliates (use the provided Link to Article).There is an urgent need for otoprotective drug agents. Prevention of noise-induced hearing loss continues to be a major challenge for military personnel and workers in a variety of industries despite the requirements that at-risk individuals use hearing protection devices such as ear plugs or ear muffs. Drug-induced hearing loss is also a major quality-of-life issue with many patients experiencing clinically significant hearing loss as a side effect of treatment with life-saving drug agents such as cisplatin and aminoglycoside antibiotics. There are no pharmaceutical agents approved by the United States Food and Drug Administration for the purpose of protecting the inner ear against damage, and preventing associated hearing loss (otoprotection). However, a variety of preclinical studies have suggested promise, with some supporting data from clinical trials now being available as well. Additional research within this promising area is urgently needed. © Georg Thieme Verlag KG, Stuttgart. New York.en©2019 Thieme Medical Publishers, Inc.Deafness, Drug inducedDeafness, Noise inducedProtection from deafnessOtotoxicityHearing LossarticleLe Prell, C. G.. 2019. "Otoprotectants: From Research to Clinical Application." Seminars in Hearing 40(2): 162-176, doi: 10.1055/s-0039-1684045402